BTG Pactual hires Charles Rosier for European business
Charles Rosier's Programmes on Environmental Consciousness
Promoting the proper usage of resources paired with awareness projects on pollution-free environment is crucial to Innoveox since they envision creating a safe environment for all by lowering carbon dioxide emissions. charles rosier (http://www.efinancialnews.com/story/2010-09-17/charles-rosier-joins-btg) is a partner at Innoveox, a French company working on fostering a friendly and pollution-free environment. To develop lanterns and other energy solutions, he extended his help by making an investment in MPOWERD. MPOWERD has supplied energy to more than 25 countries around the planet as a result. Charles Rosier has done a lot for the environment and helped with the development of energy and power sectors in poor countries.
A Glimpse at Charles Rosier’s Life
In 1996, Charles Rosier started at Lehman Brothers before later joining UBS Warburg Investment Bank. He then became the head of the finance department at Goldman Sachs Bank. He worked at BTG Pactual Bank and built a partnership until the year 2010. Environmentally-friendly activities, culture, extreme sports and studies are the things that matter to him. In 1991, Charles Rosier received his scientific degree after completing his studies at Fenelon Sainte-Marie.
Charles Rosier’s Professional Experiences
At BTG Pactual, Charles Rosier firmly imposed five major principles. (Meritocracy and Partnership, World-Class Governance, Client Focus, Global Thinking Presence and Long Term View). In 2009, Charles Rosier joined Goldman Sachs and worked as their Managing Director until 2010. Goldman Sachs (also known as GMS) is one of the best banks, worldwide, having many active branches in various countries. He focused on public-asset management as their Managing Director.
Health Related Projects
Charles Rosier invested in a pharmaceutical organisation (Mapreg) to develop a healthcare project, managed by Professor Etienne Baulieu. He also invested capital in the laboratory of Mapreg, located in Paris, to continue doing studies about serious conditions including depression and stroke. Charles Rosier funded the drug project to help find a cure for strokes that can lead to spinal cord damage.